Method for dispensing a prescription product

ABSTRACT

A method for dispensing alternative prescription products to a patient to provide the patient alternative treatment options and increase treatment protocol compliance. After a patient is diagnosed with a medical condition requiring treatment with a prescription product, the patient is provided with a kit containing a multiple continuous positive airway CPAP interfaces designed to adapt to a plurality of different facial features. Instead of being custom fitted by a CPAP interface specialist, the patient is given multiple CPAP interfaces to try and select the CPAP interface most desirable to the patient. The patient indicates the most desirable CPAP interface and, after a predetermined period of time, the patient is provided with a new CPAP interface matching the most desirable CPAP interface selected by the patient.

BACKGROUND OF THE INVENTION

1. Field of the Invention

This invention relates to a method for dispensing prescription productsand, more specifically to a method for facilitating patient empowermentby integrating patient personal choice in the selection of prescriptionphysiological interfaces.

2. Description of the Prior Art

It is generally known in the art to diagnose patients with a medicalcondition requiring treatment with a prescription device. One suchdevice is a continuous positive airway pressure (CPAP) system used totreat sleep apnea. The system includes an interface, such as a mask ornasal canula to provide the patient with pressurized air. These CPAPsystem interfaces must not only conform to the patient's specificphysiological features to objectively function, but must also besubjectively comfortable to the patient. One drawback associated withprior art CPAP sleep apnea treatment systems is the requirement that thepatient meet with a specialist to custom fit the patient with anappropriate CPAP interface.

A fitting with such a specialist is time consuming and expensive.Additionally, such fittings with a specialist do not occur during thecritical activity of sleep and therefore cannot incorporate thepatient's nocturnal movements or tendencies into the fitting procedure.As certain interfaces can inhibit or impede the patient's nocturnalmovements, a fitting which does not take these issues into account couldcause the patient to become frustrated and unhappy with the interfaceleading to a discontinuance of use. Given the limited amount offollow-up time that too often occurs between such specialists andpatients, such specialized fittings are often heavily weighted towardobjective function, rather than interference with a patient's nocturnalactivities.

Another drawback associated with such prior art devices is that evenafter the specialist and patient determine an appropriate CPAPinterface, the selection process does not take into account long termdesirability of the interface and does not allow a patient to switchback and forth between interfaces to make a better comparison andultimate selection. Unfortunately, it is often not until the patientuses the interface over a period of time that the patient determinesthat a particular interface is unacceptable. By this time, a patient maynot feel comfortable contacting the specialist for fitting an alternateinterface or obtaining an interface of a different size. The patientthen discontinues using the original mask, thereby ceasing treatment. Itwould, therefore, be desirable time, cost and comfort perspectives toeliminate one or more fittings with a specialist.

Still another drawback associated with the prior art is that properpatient compliance with CPAP therapy is generally poor. A largeimpediment to compliance is that patients often become frustrated withthe use and/or comfort of the interface and cease using the CPAP fortreatment. It has been found, however, that if the patients can complywith the treatment during the first few weeks, the compliance rate risesdramatically. Therefore, it would be highly desirable to provide meansfor assisting patients past that critical “break in” period todramatically increase the long term rate of compliance with theprescribed treatment.

Wearing equipment while sleeping often involves a difficult initialacceptance period for the patient. Prior art involves a techniciansending the patient home with a single interface. A serious flaw in thisone-at-a-time selection method is that patients are forced to make aninitial assessment of therapy comfort and decide on ultimate acceptanceof the therapy relative to the only alternative made available, namely,no treatment at all. It would therefore be desirable to give patients analternative point of relative comparison in the form of alternativeinterface choices that the patient can try from the very first nightwithin their natural sleep environment. Adding the physiologicaladvantage of self-selection empowers the patient to select one interfacesolution over another, rather than forcing the patient to select betweenan uncomfortable treatment and no treatment at all.

Although it is known in the art to provide patients with an alternativeCPAP interface in the event the patient is unsatisfied with theinitially prescribed interface, obtaining an alternative interface isoften a time consuming and difficult process. As the various interfacesare typically provided in a variety of sizes adaptable to uniquephysiological features of different patients, it would be difficult toprovide patients with the hundreds of options associated with varioussizes and types of interfaces to allow patients to personally select adesired interface. Additionally, just as a lack of immediate,comparative choices can cause a patient to quickly assess the therapy astoo difficult and cease treatment, so too can an overwhelmingly largenumber of options. An additional drawback would be the time andfrustration associated with a patient attempting to select anappropriate interface from amongst hundreds of potential interfaceoptions, most of which would not even fit the patient. It would,therefore, be desirable to provide a patient with a plurality ofoptions, while reducing the time, cost and difficulty associated withproviding such options.

The difficulties encountered in the prior art discussed hereinabove aresubstantially eliminated by the present invention.

SUMMARY OF THE INVENTION

In an advantage provided by this invention, a method is provided fordispensing a prescription product which reduces initial and overallcosts of treatment.

Advantageously, this invention provides a method for dispensing aprescription product which facilitates patient selection of the mostcomfortable and useful prescription product.

Advantageously, this invention provides a method for dispensing aprescription product which empowers a patient to continue with, and takeownership of, the most desirable treatment option.

Advantageously, this invention provides a method for dispensing aprescription product which reduces delays associated with prior artdispensing of prescription products.

Advantageously, this invention provides a method for dispensing aprescription product which increases patient compliance with prescribedtreatment using the prescription product.

Advantageously, in a preferred example of this invention, a method fordispensing a prescription product to a patient is provided. The methodcomprises diagnosing the patient with a medical condition and providingthe patient with a plurality of prescription products. Preferably, eachtype of product is adaptable to the patient's unique physiologicalfeatures. By providing the patient with a plurality of prescriptionproducts, the patient can try the different devices to determine whichdevice is most appropriate. In the preferred embodiment, theprescription products are of a universal fit type, allowing the patientto personally adjust the prescription product to comport with thepatient's unique physiological features. Preferably, the prescriptionproduct is a CPAP interface.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 illustrates a top perspective view of the CPAP kit of the presentinvention;

FIG. 2 illustrates a front perspective view of an alternativeuniversally adaptable CPAP interface utilizing a full face mask;

FIG. 3 illustrates a front perspective exploded view of an alternativeuniversally adaptable CPAP interface utilizing nasal pillows;

FIG. 4 illustrates a side perspective exploded view of an alternativeuniversally adaptable CPAP interface utilizing an oral interface;

FIG. 5 illustrates a schematic of the interaction between the entitiesassisting the patient in determining an appropriate prescription productinterface;

FIG. 6 A-D illustrates a flowchart of an exemplary process fordispensing a prescription product to a patient;

FIGS. 7 A-B illustrate the front and back of an initial contact postcardused in association with the method of the present invention.

FIG. 8A-B illustrate the front and back of a request postcard used inassociation with the method of the present invention.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

Although the prescription product of the present invention may be adelivery system, such as insulin, syringes or a consumable product, suchas pills or topical treatments, in the preferred embodiment, theprescription product is a continuous positive airway pressure (CPAP)kit, shown generally as (10) in FIG. 1. The kit (10) preferably containsinstructions (12) a filter (14) a blower (16) and a hose (18) such asthose well known in the art. The kit (10) also contains a first CPAPinterface (20) and a second CPAP interface (22).

As shown in FIG. 1, the first CPAP interface (20) is of the “nasal mask”type being provided with a mask (24) and headgear (26). The nasal mask(24) is preferably of a “universal” fit type having a malleabletriangular cushioned perimeter (28) which a patient can adjust to makelarger or smaller or to more readily fit the patient's physiology. Thesecond CPAP interface (22) is preferably a nasal canula (30), such asthose known in the art. As nasal canulas (30) are typically notmalleable, the kit is provided with six pairs of interfaces (34) (threeof which are shown), ranging from a large interface (32) to a smallinterface (36), preferably provided on a blister pack or other sterilepackaging. Although in the preferred embodiment, the first CPAPinterface (20) is a nasal mask (24) and the second CPAP interface (22)is preferably a nasal canula (30), as shown in FIGS. 2-4, the CPAPinterfaces (20) and (22) may be of any type known in the art, such as afull face mask (38), a nasal pillow system (40) an oral delivery system(42) or any other type of delivery system known in the art.

Preferably, both the first CPAP interface (20) and the second CPAPinterface (22) are “universally adaptable” systems designed to adapt toa large number of patient physiological features. The universallyadaptable feature may be the adjustability of the full face mask (38),the provision of various different sized interfaces for the nasal pillowsystem (40), the inherent adaptability to a large number of patients asis the case with the oral delivery system (42) or any other adaptabilityfeature which reduces the need for a unique, customized interface. Thefact that the CPAP interfaces (20) and (22) are systems designed toadapt to a large number of patient physiological features has a two-foldbenefit. First, inventory is reduced as only a single kit is necessaryto accommodate a broad range of patients. Second, the adaptability aidsthe patient in adjusting the system to patient's own physiologicalfeatures and increases comfort and compliance by reducing the likelihooda patient will end up with an ill fitting or ineffective interface.

As shown in FIGS. 5 and 6A, the process of the present invention beginswith step (44), where a patient (46) visits a physician (48), whoprescribes an overnight sleep study in a sleep lab. The patient (46)participates in a study wherein data is collected by a sleep technician.The data is later reviewed by the physician (48) who diagnoses thepatient (46) with a condition, such as obstructive sleep apnea, andprescribes a CPAP system for the patient (46).

In step (50), the patient (46) contacts a prescription product provider(PPP) (52), such as a durable medical equipment provider and providesthe PPP (52) with the prescription and the patient's information,including insurance coverage information. In step (54), the PPP (50)provides the patient (46) with the CPAP kit (10), education about use ofthe CPAP kit (10), an introductory newsletter and a product renewalauthorization. The product renewal authorization contains the patient'sinformation and information regarding the patient's insurance authorizedreplenisment cycles. The patient (46) signs and returns theauthorization to the PPP (50), and takes the CPAP kit (10).

In step (56) the PPP (52) provides the patient information and deliverydate to the product manufacturer (PM) (58) of the kit (10). In step(60), the PM (58) enters the delivery date and patient information intoa secure database (62) and provides the delivery date and patientinformation to a product fulfillment coordinator (PFC) (64).

In step (66), the PFC (64) records the patient information and docketsthe delivery date (FIG. 6A). Using the patient's insurance coverageinformation, the PFC (64) uses the delivery date to docket the dates thepatient's insurance carrier is willing to pay to replace variouscomponents of the kit (10). In step (68), the PFC's computerized docketsystem (70) reminds the PFC (64) when it is time to contact the patient(40). In step (70), when it is time to contact the patient (40), the PFC(64) checks to see if this is the first time the PFC (64) has contactedthe patient (46). If it is the first time the PFC (64) has contacted thepatient (46), in step (74) the PFC (64) generates and sends the patient(46) an introductory newsletter (76) such as the one shown in FIG. 7A.

As shown in FIG. 7A, the introductory newsletter (76) contains a postagepaid detachable patient introduction postcard (78) addressed to the PFC(64). The introductory newsletter (76) preferably provides informationrelated to the CPAP kit (10). The more valuable this information, theless likely the patient is to discard the introductory newsletter (76)and the more likely the patient is to read the introductory newsletter(76). As shown in FIG. 7B the reverse side of the patient introductionpostcard (78) contains a textual greeting (80), a response section (82),for the patient to indicate the patient's preference of interface, andinstructions (84) for completing and returning the patient introductionpostcard (78). If patient authorization has not already been obtained,the response section (82) may contain a signature requirement toauthorize use of the patient's medical information. As many statutesrequire written patient authorization, the instant system has asignificant advantage over prior art telephony based systems. The morevaluable the information is on the introductory newsletter (76), themore likely the patient is to fill out and return the patientintroduction postcard (78) which may authorize future contact with thepatient and/or additional use of the patient's information. Valuableinformation on the introductory newsletter (76), the more the patientwill look forward to the next newsletter and the more likely the patientwill order additional supplies. The PFC (64) preferably provides thepatient introduction postcard (78) with a barcode (86) associated withthe patient (46). By the time the patient (46) has received the patientintroduction postcard (78), the patient (46) has had sufficient time todetermine a personal preference between the first CPAP interface (20)and the second CPAP interface (22).

In step (88), the patient (46) records the preferential prescriptionproduct on the patient introduction postcard (78) and mails the patientintroduction postcard (78) to the patient (46) (FIGS. 6A and 7B). Instep (90) the PFC (64) receives the patient introduction postcard (78),reads the barcode (86) with a scanner (not shown) such as those wellknown in the art and records the patient selection on the patientintroduction postcard (78). The PFC (64) then transmits the informationfrom the patient introduction postcard (78) to the PM (58), and recordsthe patient's preferential prescription product information into thedatabase (62). After the PFC (64) has recorded this information into thedatabase (62) or if in step (72) it is not the first contact with thepatient (46), the process moves to step (92) where the PM (58) checksthe patient's insurance coverage and frequency of replacement ofprescription products thereunder and relays this information to the PFC(64) (FIGS. 5 and 6A-B).

Once, as shown in step (94), monthly, the PFC (64) checks its docketsystem (70) to determine if it is time to contact the patient (46). Inthe event the docket system indicates it is time to contac the patient(46), the PFC (64) checks the patient's insurance-driven replenishmentrates to determine and customize content in the patient's newslettercontent. If the patient (46) is due for replenishment of a CPAP hose(18), the newsletter may be customized to extol the dangers of hosefailure. The process moves to step (96) where the PFC (64) checks to seeif the patient's insurance company (98) authorizes a new CPAP hose (18)for the patient (46) at this time period. If, as shown in step (100),the patient's insurance company (98) does authorize a new CPAP hose (18)for the patient (46) at this time period, the PFC (64) “checks” the box(102) marked “hose” on the detachable patient refill postcard (106)section of a refill newsletter (104) provided with by the PFC (64), suchas the one shown in FIG. 8A. The refill postcard (106) is preferablypostage paid and addressed to the PFC (64). As shown in FIG. 8B, thereverse side of the refill postcard (106) contains a textual greeting(108), a response section (110), preferably already filled out by thePFC (64), instructions (112) for completing and returning the refillpostcard (106), and a patient signature line (114) and date line (116).The PFC (64) also preferably provides the refill postcard (106) with abarcode (118) associated with the patient (46).

As shown in FIGS. 6B and 8B, after the box (102) has been marked in step(100), or if the insurance company (98) does not authorize a new CPAPhose (18) for the patient (46) at this time period, the process moves tostep (120) where the PFC (64) checks to see if the patient's insurancecompany (98) authorizes a new CPAP filter (14) for the patient (46) atthis time period. If, as shown in step (122), the patient's insurancecompany (98) does authorize a new CPAP filter (14) for the patient (46)at this time period, the PFC (64) “checks” the box (124) marked “filter”on the refill postcard (106) section of a refill newsletter (104) (FIGS.1, 5, 6B and 8A-B).

As shown in FIG. 6B, after the box (124) has been marked in step (100),or if the insurance company (98) does not authorize a new CPAP filter(14) for the patient (46) at this time period, the process moves to step(126) where the PFC (64) checks to see if the patient's insurancecompany (98) authorizes a new CPAP interface for the patient (46) atthis time period. If the patient's insurance company (98) does authorizea new CPAP interface for the patient (46) at this time period, the PFC(64) queries the database (62) to determine the patient's preferentialprescription product (130) previously identified by the patient (46) onthe patient introduction postcard (78) and entered into the database(62) by the PFC (64). As shown in Step (128) the PFC (64) then insertsthe name of the patient's preferential prescription product (130) on therefill postcard (106) and “checks” the box (132) adjacent the name ofthe patient's preferential prescription product (130). (FIGS. 1, 6B and8A-B).

As shown in FIGS. 6B-C, after the box (132) has been marked in step(128), or if the insurance company (98) does not authorize a new CPAPinterface for the patient (46) at this time period, the process moves tostep (134) where the PFC (64) checks to see if the patient's insurancecompany (98) authorizes new CPAP headgear (26) for the patient (46) atthis time period. If, as shown in step (136), the patient's insurancecompany (98) does not authorize new CPAP headgear (26) for the patient(46) at this time period, the PFC (64) does not “check” the box (138)marked “headgear” on the refill postcard (106) section of a refillnewsletter (104) (FIGS. 1, 6C and 8A-B).

Although the foregoing steps may be implemented manually, in thepreferred embodiment, the process is automatic, with the PFC (64)running a central processing unit (CPU) (140) such as those known in theart. As shown in FIG. 5, the CPU (140) is coupled to the docket system(70) and the database (62). The CPU (140) is also preferably coupled toa standard color printer (142). When the docket system (70) indicates itis time for the patient (46) to receive correspondence, the CPU (140)obtains the appropriate information from the docket system (70) anddatabase (62) and generates the appropriate newsletter (76) or (104)personalized with the patient's name and other pertinent information(FIGS. 5 and 6A-D). The CPU (140) personalizes the postcard (78) or(106), as described above, with the patient's refill information andencodes the postcard (78) or (106) with appropriate postage and thebarcode (86) or (118) identifying information on the postcard (78) or(106). The foregoing steps are, of course, only examples, as the processmay be used to refill any number or type of prescription products suchas pharmaceuticals, insulin delivery systems, diabetic maintenancesupplies or any other prescription products.

As shown in step (144), once the refill newsletter (104) is prepared,the PFC (64) mails the refill newsletter (104) to the patient (46) (FIG.6C). In step (146), the patient (46) receives the newsletter (104),detaches the refill postcard (106), signs and dates it as indicated andmails it back to the PFC (64). Upon receipt of the executed refillpostcard (106), the PFC (64) checks for proper execution of the postcard(106) and reads the barcode (118) into the CPU (140). If desired, theentire postcard can be scanned in to the database (62) using opticalcharacter recognition software to facilitate the storage, retrieval andtransmission of the authorizations contained thereon. In step (148), thePFC (64) forwards the order information from the executed refillpostcard (106) to the PPP (52), which, as indicated in step (150),forwards the order information on to the PM (58).

Upon receipt of the order information, in step (152) the PM (58) sendsthe appropriate refill prescription products directly to the patient(46) and sends confirmation to the PPP (52) that the order has beenreceived and product sent. Alternatively, the PM (58) could send theproducts to the PPP (52) which, in turn, forwarded the products to thepatient (46). As shown in step (154), upon notice that the product hasbeen sent, the PPP (52) forwards the information onto the patient'sinsurance company (98) for reimbursement. As shown in step (156), uponreceipt of the reimbursement request, the patient's insurance company(98) reimburses payment to the PPP (52) (FIGS. 5 and 6D). Upon receiptof the reimbursement, in step (158) the PPP (52) pays the PM (58).Preferably the PM (58) pays the PFC (64) based upon volume, independentof receipt of any reimbursement.

As shown in step (160), if the patient (46) ever decides to try analternative interface, such as the full face mask (38), the nasal pillowsystem (40), the oral delivery system (42) or any other system, thepatient (46) in Step (162) indicates to the PFC (64) that an alternativeinterface is desired. The indication can be made on the refill postcard(106), by directly contacting the PFC (64) or PPP (52) or by any otherdesired means. Upon receipt of an alternative interface selectionpreference from the patient (46) in Step (164), the PFC (64) inputs theinformation into the database (62). In step (166), the PFC (64) forwardsthe alternative interface selection preference information to the PPP(52), which, as indicated in step (163), forwards the order informationon to the PM (58).

After receipt of the alternative interface selection preference, at theappropriate time, in step (170) the PM (58) sends the alternativeinterface and associated prescription products directly to the patient(46) and in Step (172) sends confirmation to the PPP (52) that thealternative interface selection preference has been received andalternative interface and associated prescription products sent. Asshown in step (174), upon notice that the alternative interface andassociated prescription products have been sent, the PPP (52) forwardsthe information onto the patient's insurance company (98) forreimbursement. The process returns to step (156) where, upon receipt ofthe reimbursement request, the patient's insurance company (98)reimburses payment to the PPP (52) (FIGS. 5 and 6D). Upon receipt of thereimbursement, in step (158) the PPP (52) again pays the PM (58).

If the patient (46) dies does not desire an alternative interface, inStep (160), the process moves to Step (176). If the patient dies, or nolonger wishes to receive prescription products, or fails to return apredetermined number of refill postcards (106), the PM (58) issues astop delivery order. If as shown in step (178), a stop delivery order isreceived, the process terminates in step (180) and the PM (58) instructsthe PFC (64) to stop providing newsletters (104) to the patient (46). Ifno stop delivery order is received, however, the process returns to step(68), where the PFC (46) awaits the next docket date to prepare and senda newsletter (104) to the patient (46).

Although the invention has been described with respect to a preferredembodiment thereof, it to be also understood that is not to be solimited, since changes and modifications can be made therein which arewithin the full, intended scope of this invention as defined by theappended claims. For example, it should be noted the PPP (52), PM (58)and PFC (64) may all be a single entity, with the process beingautomated and with barcode readers automatically entering informationfrom incoming postcards (106) and automatically sending out newslettersat appropriate intervals. Additionally, alternative means ofcommunication may be used, such as instant messaging, electronic mail,text messaging or any other type of textual communication.

1. A method for dispensing a prescription product to a patientcomprising the steps of: (a) diagnosing said patient with a medicalcondition; (b) providing said patient with a first prescription product,wherein said first prescription product is provided with means foradapting said first prescription product to a plurality of physiologicalfeatures of said patient; (c) providing said patient with a secondprescription product, wherein said second prescription product isprovided with means for adapting said second prescription product to aplurality of physiological features of said patient; (d) adapting saidfirst prescription product to physiological features of said patient;and (e) said patient selecting a preferential prescription product fromsaid first prescription product and said second prescription product. 2.The method for dispensing a prescription product of claim 1, furthercomprising providing said patient with a replacement preferentialprescription product.
 3. The method for dispensing a prescriptionproduct of claim 1, wherein said first prescription product is acontinuous positive airway pressure interface.
 4. The method fordispensing a prescription product of claim 3, wherein said secondprescription product is a supplemental continuous positive airwaypressure interface.
 5. The method for dispensing a prescription productof claim 1, wherein said first prescription product is a mask.
 6. Themethod for dispensing a prescription product of claim 5, wherein saidsecond prescription product is an inner nasal interface.
 7. The methodfor dispensing a prescription product of claim 5, further comprisingpermanently deforming said mask to conform to a facial feature of saidpatient.
 8. The method for dispensing a prescription product of claim 7,wherein said second prescription product is an inner nasal interfaceprovided with at least two pairs of nasal interfaces.
 9. The method fordispensing a prescription product of claim 8, further comprisingproviding said patient with said mask and said inner nasal interface atthe same time.
 10. The method for dispensing a prescription product ofclaim 1, further comprising providing said patient with a textualproduct request and wherein said step of selecting comprises identifyingsaid preferential prescription in a response to said textual productrequest.
 11. The method for dispensing a prescription product of claim1, wherein said patient selects said preferential prescription productat least twenty days after providing patient with said firstprescription product and said second prescription product.
 12. Themethod for dispensing a prescription product of claim 1, furthercomprising adapting said second prescription product to saidphysiological features of said patient.
 13. A method for dispensing aprescription product to a patient comprising the steps of: (a)diagnosing said patient with a medical condition; (b) providing saidpatient with a first prescription product, wherein said firstprescription product is provided with means for adapting said firstprescription product to a plurality of physiological features of saidpatient; (c) providing said patient with a second prescription product,wherein said second prescription product is provided with means foradapting said second prescription product to a plurality ofphysiological features of said patient; (d) adapting said firstprescription product to a plurality of physiological features of saidpatient; (e) querying said patient after a predetermined time as to saidpatient's preferential prescription product selected from said firstprescription product and said second prescription product; and (f)providing said patient with another preferential prescription product.14. The method for dispensing a prescription product of claim 13,further comprising providing said patient with said first prescriptionproduct and said second prescription product at the same time.
 15. Themethod for dispensing a prescription product of claim 13, wherein saidfirst prescription product is a continuous positive airway pressureinterface.
 16. The method for dispensing a prescription product of claim13, wherein said first prescription product is a mask.
 17. The methodfor dispensing a prescription product of claim 16, wherein said secondprescription product is an inner nasal interface.
 18. The method fordispensing a prescription product of claim 13, wherein said queryingcomprises the steps of: (a) providing said patient with a textualproduct request; and (b) receiving a response to said textual productrequest from said patient.
 19. A method for dispensing a continuouspositive airway pressure system to a patient comprising the steps of:(a) diagnosing said patient with a medical condition; (b) providing saidpatient with a continuous positive airway pressure system kit, said kitcomprising: (i) a continuous positive airway pressure mask, wherein saidmask is configured to be reconfigured to adapt to a plurality ofdifferent facial features; (ii) a plurality of different sizedcontinuous positive airway pressure nasal interfaces. (c) said patientselecting a preferential interface from said continuous positive airwaymask and said plurality of continuous positive airway nasal interfaces;and (d) providing said patient with another preferential interface. 20.The method for dispensing a prescription product of claim 19, furthercomprising the steps of: (a) querying said patient as to saidpreferential interface; (b) said patient responding to said query; and(c) wherein said step of providing said patient with anotherpreferential interface is done in response to said step of said patientresponding to said query.